Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joinn Laboratories (China) CoSHSE:603127 +3.72%78 Pretax Margin % is 81.00% as of Mar. 2026, which is 160% above its 10-year median of 31.15. GuruFocus rates SHSE:603127 with a GF Score™ of 78/100 and a GF Value™ of ¥17.43 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks better than 98.01% on this metric.
The historical rank and industry rank for Joinn Laboratories (China) Co's Pretax Margin % or its related term are showing as below:
SHSE:603127'
s Pretax Margin % Range Over the Past 10 Years
Min: 5.15 Med: 31.15 Max: 54.67
Current: 32.27
SHSE:603127's Pretax Margin % is ranked better than 98.01% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.57
vs SHSE:603127: 32.27
Joinn Laboratories (China) Co (SHSE:603127) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Joinn Laboratories (China) Co Pretax Margin % Related Terms
Joinn Laboratories (China) Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co Pretax Margin % Chart
SHSE:603127 vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) has a Pretax Margin % of 81.00% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Joinn Laboratories (China) Co and its competitors. This is 160% above median its historical median of 31.15. Over the past decade, Joinn Laboratories (China) Co's Pretax Margin % has ranged from 5.15 to 54.67. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #4 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 2%.
Is Joinn Laboratories (China) Co's Pretax Margin % too high?
Joinn Laboratories (China) Co's current Pretax Margin % of 81.00% is 160% above median its 10-year median of 31.15. Over the past 10 years, this metric has ranged from a low of 5.15 to a high of 54.67. Based on the distribution chart, Joinn Laboratories (China) Co ranks #4 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #4 out of 201 companies for Pretax Margin %. This places Joinn Laboratories (China) Co in the top 2% of its industry — outperforming the majority of peers. Historically, Joinn Laboratories (China) Co's own Pretax Margin % has ranged from 5.15 to 54.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Joinn Laboratories (China) Co and its competitors. Joinn Laboratories (China) Co's current Pretax Margin % is 81.00%, which is 160% above median its own 10-year median of 31.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current Pretax Margin % is 81.00%, which is 160% above median its 10-year median of 31.15. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Pretax Margin % is 81.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
Pretax Margin %: 81.00% (160% above median its 10-year median of 31.15)
GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
